Condition: Breast Cancer · HER2-positive Breast Cancer · TNBC - Triple-Negative Breast Cancer · Sponsor: Indiana University
The purpose of this study is to assess the feasibility of the NearWave optical molecular monitoring system for monitoring therapy progression and predicting pathologic complete response (pCR) of breast cancer patients undergoing neoadjuvant chemotherapy (NAC).
This description comes directly from the study's public registry record.
Tarah J Ballinger, MD · (317) 944-3553 · tarahb@iu.edu
Xin Bryan, RN · 317-312-2793 · zhongx@iu.edu
Always discuss trial participation with your own doctor first.
| Indiana University Simon Comprehensive Cancer Center | Indianapolis, Indiana, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06744465